Melatonin Anticancer Effects: Review

被引:130
作者
Di Bella, Giuseppe [1 ]
Mascia, Fabrizio [1 ]
Gualano, Luciano [2 ]
Di Bella, Luigi [2 ]
机构
[1] Di Bella Fdn, I-40122 Bologna, Italy
[2] Private Lab Physiol, I-41123 Modena, Italy
来源
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2013年 / 14卷 / 02期
关键词
melatonin; apoptosis; angiogenesis; APUD system; Di Bella Method; PINEAL HORMONE MELATONIN; CYCLOPHOSPHAMIDE PLUS SOMATOSTATIN; DBM IMPROVED SURVIVAL; NON-HODGKINS-LYMPHOMA; BREAST-CANCER CELLS; PROTEIN-KINASE-C; LOW-DOSE IL-2; GROWTH-FACTOR; VITAMIN-D; PHASE-II;
D O I
10.3390/ijms14022410
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Melatonin (N-acetyl-5-methoxytryptamine, MLT), the main hormone produced by the pineal gland, not only regulates circadian rhythm, but also has antioxidant, anti-ageing and immunomodulatory properties. MLT plays an important role in blood composition, medullary dynamics, platelet genesis, vessel endothelia, and in platelet aggregation, leukocyte formula regulation and hemoglobin synthesis. Its significant atoxic, apoptotic, oncostatic, angiogenetic, differentiating and antiproliferative properties against all solid and liquid tumors have also been documented. Thanks, in fact, to its considerable functional versatility, MLT can exert both direct and indirect anticancer effects in factorial synergy with other differentiating, antiproliferative, immunomodulating and trophic molecules that form part of the anticancer treatment formulated by Luigi Di Bella (Di Bella Method, DBM: somatostatin, retinoids, ascorbic acid, vitamin D3, prolactin inhibitors, chondroitin-sulfate). The interaction between MLT and the DBM molecules counters the multiple processes that characterize the neoplastic phenotype (induction, promotion, progression and/or dissemination, tumoral mutation). All these particular characteristics suggest the use of MLT in oncological diseases.
引用
收藏
页码:2410 / 2430
页数:21
相关论文
共 166 条
[81]   Circadian secretions of IL-2, IL-12, IL-6 and IL-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans [J].
Lissoni, P ;
Rovelli, F ;
Brivio, O ;
Fumagalli, L .
NATURAL IMMUNITY, 1998, 16 (01) :1-5
[82]   Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms [J].
Lissoni, P. .
PATHOLOGIE BIOLOGIE, 2007, 55 (3-4) :201-204
[83]   THE CLINICAL-SIGNIFICANCE OF MELATONIN SERUM DETERMINATION IN ONCOLOGICAL PATIENTS AND ITS CORRELATIONS WITH GH AND PRL BLOOD-LEVELS [J].
LISSONI, P ;
BASTONE, A ;
SALA, R ;
MAURI, R ;
ROVELLI, F ;
VIVIANI, S ;
BAJETTA, E ;
ESPOSTI, D ;
ESPOSTI, G ;
DIBELLA, L ;
FRASCHINI, F .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (07) :949-957
[84]  
Lissoni P, 1997, J BIOL REG HOMEOS AG, V11, P119
[85]  
Lissoni P, 2001, NEUROENDOCRINOL LETT, V22, P45
[86]   Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status [J].
Lissoni, P ;
Barni, S ;
Mandalà, M ;
Ardizzoia, A ;
Paolorossi, F ;
Vaghi, M ;
Longarini, R ;
Malugani, F ;
Tancini, G .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (12) :1688-1692
[87]  
LISSONI P, 1991, ONCOLOGY-BASEL, V48, P448
[88]  
Lissoni P, 2000, NEUROENDOCRINOL LETT, V21, P319
[89]  
Lissoni P, 2000, ANTICANCER RES, V20, P2103
[90]   SYNERGISTIC ACTION OF MELATONIN AND VASOACTIVE-INTESTINAL-PEPTIDE IN STIMULATING CYCLIC-AMP PRODUCTION IN HUMAN-LYMPHOCYTES [J].
LOPEZGONZALEZ, MA ;
CALVO, JR ;
OSUNA, C ;
RUBIO, A ;
GUERRERO, JM .
JOURNAL OF PINEAL RESEARCH, 1992, 12 (04) :174-180